KR102513800B1 - (r)-2-아미노-3-페닐프로필 카바메이트의 용매화물 폼 - Google Patents

(r)-2-아미노-3-페닐프로필 카바메이트의 용매화물 폼 Download PDF

Info

Publication number
KR102513800B1
KR102513800B1 KR1020197011279A KR20197011279A KR102513800B1 KR 102513800 B1 KR102513800 B1 KR 102513800B1 KR 1020197011279 A KR1020197011279 A KR 1020197011279A KR 20197011279 A KR20197011279 A KR 20197011279A KR 102513800 B1 KR102513800 B1 KR 102513800B1
Authority
KR
South Korea
Prior art keywords
amino
carbamate hydrochloride
phenylpropyl carbamate
composition
apc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197011279A
Other languages
English (en)
Korean (ko)
Other versions
KR20190065311A (ko
Inventor
제니퍼 레이 넬슨
피온 헐리
Original Assignee
에스케이바이오팜 주식회사
재즈 파마슈티칼즈 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61562003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102513800(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에스케이바이오팜 주식회사, 재즈 파마슈티칼즈 아일랜드 리미티드 filed Critical 에스케이바이오팜 주식회사
Publication of KR20190065311A publication Critical patent/KR20190065311A/ko
Application granted granted Critical
Publication of KR102513800B1 publication Critical patent/KR102513800B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/08—Separation; Purification; Stabilisation; Use of additives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020197011279A 2016-09-06 2017-09-06 (r)-2-아미노-3-페닐프로필 카바메이트의 용매화물 폼 Active KR102513800B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383822P 2016-09-06 2016-09-06
US62/383,822 2016-09-06
PCT/US2017/050233 WO2018048871A1 (en) 2016-09-06 2017-09-06 Solvate form of (r)-2-amino-3-phenylpropyl carbamate

Publications (2)

Publication Number Publication Date
KR20190065311A KR20190065311A (ko) 2019-06-11
KR102513800B1 true KR102513800B1 (ko) 2023-03-24

Family

ID=61562003

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197011279A Active KR102513800B1 (ko) 2016-09-06 2017-09-06 (r)-2-아미노-3-페닐프로필 카바메이트의 용매화물 폼

Country Status (13)

Country Link
US (4) US10829443B2 (enExample)
EP (2) EP3509582B1 (enExample)
JP (3) JP7219213B2 (enExample)
KR (1) KR102513800B1 (enExample)
CN (2) CN109996540A (enExample)
CA (1) CA3036071A1 (enExample)
DK (1) DK3509582T3 (enExample)
ES (1) ES2970887T3 (enExample)
FI (1) FI3509582T3 (enExample)
MY (1) MY197630A (enExample)
PH (1) PH12019500493A1 (enExample)
SG (1) SG11201901998WA (enExample)
WO (1) WO2018048871A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3509582B1 (en) * 2016-09-06 2023-12-20 Axsome Malta Ltd. Solvate form of (r)-2-amino-3-phenylpropyl carbamate
EP3837239A4 (en) 2018-08-14 2022-05-18 Glenmark Life Sciences Limited Process for the preparation of solriamfetol and salt thereof
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
WO2021001457A1 (en) 2019-07-04 2021-01-07 Sandoz Ag Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
IT202000013855A1 (it) * 2020-06-10 2021-12-10 Flamma Spa Un processo per la purificazione del (r)-2-ammino-3-fenilpropil carbammato
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2024102718A1 (en) * 2022-11-07 2024-05-16 Axsome Therapeutics Compositions and methods for treating insomnia
CN120641090A (zh) * 2022-12-30 2025-09-12 阿克苏姆马耳他有限公司 向哺乳期女性施用索安非托的方法
WO2024194718A1 (en) 2023-03-22 2024-09-26 Unichem Laboratories Limited A stable pharmaceutical composition and process for preparing thereof
WO2024249560A1 (en) 2023-05-30 2024-12-05 Axsome Therapeutics, Inc. Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025042959A1 (en) 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
JP2007508293A (ja) * 2003-10-08 2007-04-05 エスケー コーポレイション 活性アミン基の存在下におけるｏ−カルバモイル化合物の製造方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
JP4374441B2 (ja) 1998-12-23 2009-12-02 ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤
RU2202607C2 (ru) * 2000-03-03 2003-04-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" Штамм бактерий methylophilus methylotrophus - продуцент l-фенилаланина (варианты), способ получения l-фенилаланина
AU2005302589B2 (en) 2004-10-28 2010-09-16 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
KR101335941B1 (ko) 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 수면-각성 장애의 치료
ATE459393T1 (de) 2005-06-22 2010-03-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
CN106727486A (zh) 2009-06-22 2017-05-31 爱思开生物制药株式会社 治疗或预防疲劳的方法
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
SI2968208T1 (sl) 2013-03-13 2023-02-28 Jazz Pharmaceuticals Ireland Limited, Zdravljenje katapleksije
KR20210152011A (ko) 2013-07-12 2021-12-14 에스케이바이오팜 주식회사 금연의 촉진
WO2015010014A1 (en) 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
WO2017140778A1 (en) 2016-02-16 2017-08-24 The University Of Queensland Sulfonylureas and related compounds and use of same
EP3509582B1 (en) * 2016-09-06 2023-12-20 Axsome Malta Ltd. Solvate form of (r)-2-amino-3-phenylpropyl carbamate
KR101950254B1 (ko) 2016-09-21 2019-02-20 유상신 차량탑승자의 부재를 감지하는 지능형 카시트
EP3837239A4 (en) * 2018-08-14 2022-05-18 Glenmark Life Sciences Limited Process for the preparation of solriamfetol and salt thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
JP2007508293A (ja) * 2003-10-08 2007-04-05 エスケー コーポレイション 活性アミン基の存在下におけるｏ−カルバモイル化合物の製造方法

Also Published As

Publication number Publication date
SG11201901998WA (en) 2019-04-29
US20210053912A1 (en) 2021-02-25
JP7642506B2 (ja) 2025-03-10
US11560354B2 (en) 2023-01-24
EP3509582A1 (en) 2019-07-17
US20250340509A1 (en) 2025-11-06
US12384743B2 (en) 2025-08-12
EP4364794A2 (en) 2024-05-08
JP2022003062A (ja) 2022-01-11
CN109996540A (zh) 2019-07-09
EP4364794A3 (en) 2024-07-24
US20230183172A1 (en) 2023-06-15
US20190194126A1 (en) 2019-06-27
KR20190065311A (ko) 2019-06-11
MY197630A (en) 2023-06-29
CA3036071A1 (en) 2018-03-15
CN120574152A (zh) 2025-09-02
EP3509582B1 (en) 2023-12-20
JP2019535643A (ja) 2019-12-12
US10829443B2 (en) 2020-11-10
ES2970887T3 (es) 2024-05-31
JP7219213B2 (ja) 2023-02-07
EP3509582A4 (en) 2020-05-13
FI3509582T3 (fi) 2024-02-08
WO2018048871A1 (en) 2018-03-15
PH12019500493A1 (en) 2019-05-27
DK3509582T3 (en) 2024-02-12
JP2024178291A (ja) 2024-12-24

Similar Documents

Publication Publication Date Title
KR102513800B1 (ko) (r)-2-아미노-3-페닐프로필 카바메이트의 용매화물 폼
KR101612642B1 (ko) 테노포비어 알라펜아미드 헤미푸마레이트
ES2776395T3 (es) Forma cristalina de ribósido de nicotinamida
EP1485388A2 (en) Topiramate salts and compositions comprising and methods of making and using the same
TW200944508A (en) Novel solid forms of bendamustine hydrochloride
JP2020530837A (ja) カルバモイルフェニルアラニノール類縁体およびその使用
US20240034718A1 (en) Salts and solid forms of (r)-1-(5-methoxy-1h-indol-1-yl)-n,n-dimethylpropan-2-amine
CN101671337A (zh) 枸橼酸爱地那非晶型a及其制备方法和用途
KR20140111044A (ko) 구연산아일데나필 결정 형태 o 및 그의 제조방법과 용도
WO2018130063A1 (zh) (r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途
US12492192B2 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
CA2579119C (en) Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan
CN121202731A (zh) (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的晶体、其组合物及用途
CN121202730A (zh) (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的制备方法、其组合物及用途
HK40009279A (en) Solvate form of (r)-2-amino-3-phenylpropyl carbamate
CN118647618A (zh) Rabeximod化合物
TW200918065A (en) Imidazopyridazine derivatives
CN102770416A (zh) 美他沙酮共晶体
HK40018109A (en) Tenofovir alafenamide hemifumarate
WO2023105483A1 (en) Crystalline forms of a 5-aminopyrazole compound useful for treating hbv
WO2011069944A1 (en) Crystalline {(3s)-3-[({1-[(2r)-2-carboxy-4-(1-naphthyl)butyl]cyclopentyl}-carbonyl)amino]-2-oxo-2,3,4,5-tetrahydro-1h-1benzazepin-1-yl}acetic acid, its preparation and use
ZA200407377B (en) Topiramate salts and compositions comprising and methods of making and using the same.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4